Cutaneous polyarteritis nodosa: skin nodules, livedo, ulcers and treatment limits

Cutaneous polyarteritis nodosa (cutaneous PAN, cPAN or cutaneous arteritis) is inflammation of arteries in the deeper skin and tissue beneath it. It can cause painful nodules, a mottled net-like pattern and ulcers. Confidence is high that biopsy and assessment for disease elsewhere matter; confidence in a definitive treatment ranking is low. Clinical classification review. Skin-limited disease needs its own care plan rather than an automatic systemic-PAN regimen.

Table of contents

• Evidence summary
• What cutaneous PAN is
• How it works and how it is diagnosed
• Treatments and their evidence limits
• Supplement and lifestyle evidence
• What works and what is not established
• Risks, side effects and urgent warning signs
• Interactions and situations needing extra care
• Who needs assessment
• Clinician-led treatment and practical use
• Animal and in vitro evidence
• Funding and source roles
• Frequently asked questions
• Sources and funding notes

Evidence summary

The first question is whether arterial inflammation is confined to the skin or belongs to a systemic or genetic disorder. The August 2026 review distinguishes single-organ skin disease from systemic PAN and forms with a defined cause. Similar-looking lesions do not settle that distinction.

A milder average outlook than systemic PAN does not mean that painful ulcers, infection or a new neurologic deficit can be ignored. No fixed progression percentage or guaranteed harmless course is supplied.

What cutaneous PAN is

The affected structures are muscular arteries around the deep dermis and subcutaneous tissue. The original Japanese histology review describes necrotizing arterial inflammation. This means injury within the arterial wall; it does not mean that every blood vessel in a skin sample is inflamed.

Tender lumps, livedo and ulceration can be prominent. The dated DermNet symptom account is useful for recognizing this range, although its older treatment anecdotes are not used as proof of benefit. A photograph can document a change but cannot establish the artery type involved.

“Cutaneous vasculitis” is a broad label. Cutaneous small-vessel vasculitis, livedoid vasculopathy and cutaneous arteritis have different assessment and treatment implications. Ask which biopsy finding supports the specific diagnosis and whether the report was interpreted with the full clinical history.

How it works and how it is diagnosed

Inflammation and obstruction can impair blood supply to skin. Immune-complex mechanisms have been proposed, but the initiating cause is often uncertain. NHLBI cause context. An association with infection does not establish that every episode is caused by an infection or requires preventive antibiotics.

A biopsy needs to reach the relevant deeper arteries; a superficial sample can miss them. The original review emphasizes depth and lesion selection. A negative or nonspecific specimen may require reconsideration by the clinical/pathology team rather than a conclusion that the symptoms are imagined.

Assessment also asks whether nerves, kidneys, gastrointestinal tract or other organs are involved. NHLBI diagnostic context. Blood/urine testing and further investigations are chosen for the presentation. Neither a normal inflammatory marker nor an abnormal antibody result can independently answer every question.

Pain, tingling or muscle symptoms near affected skin can occur, as discussed in the 2022 clinical review. Symptoms outside that territory require reassessment for wider disease or another cause. The clinician should explain what is considered local, systemic or unrelated.

Treatments and their evidence limits

The treatment goal is to control active inflammation, heal or protect damaged skin, relieve pain and preserve function. The general NHLBI treatment overview describes how vasculitis care depends on vessel type, organ involvement and severity; it is not a cutaneous-PAN drug-comparison trial.

Dermatologists/rheumatologists may use anti-inflammatory medicines, including glucocorticoids, colchicine or dapsone, and selected steroid-sparing treatment for difficult disease. The dated specialist education page describes clinical use, but listing a medicine is not proof that it is best or that everyone needs it.

The original review explicitly describes limited controlled treatment evidence. Severe, recurring or ulcerating disease can require a different plan from uncomplicated nodules. No personal medicine choice, dose or taper is provided here.

The 2021 systemic-PAN guideline excludes cutaneous PAN from its scope. Its severe systemic disease regimen must not be copied automatically into a skin-limited case. If escalation is proposed, ask which current finding justifies it and what alternative has been considered.

Supplement and lifestyle evidence

No conflict-cleared human evidence identified here shows that a supplement stops cutaneous arterial inflammation, prevents relapse or reliably heals vasculitic ulcers. A deficiency or steroid-related bone-health need may merit separate care; that does not make the nutrient a treatment for this vasculitis.

The NCCIH safety guidance explains why supplement interactions and incomplete safety information matter. Bring a list of ingredients, including herbal preparations, to the pharmacist or prescriber. An “immune boosting” claim does not establish an appropriate action in immune-mediated vascular disease.

The practical activity plan should account for ulcer location, pain and sensory changes. Ask about footwear, dressings, work demands and safely maintaining movement. Avoid applying an exercise or compression regimen taken from a different leg condition without assessment of this one.

Smoking avoidance, prescribed vascular-risk care and follow-up support general health. NHLBI living-with context. They complement disease-specific assessment. Improvement after rest, a dietary change or a new product alone cannot identify which component altered disease activity.

What works and what is not established

A useful outcome record separates new inflammatory lesions, healing, pain, nerve function and medicine toxicity. Photographs with dates and the site of each lesion can help discussions. A scar or pigment change is not necessarily ongoing active arteritis, while a newly painful ulcer needs review.

The clinical review discusses relapsing courses and differences between cohorts. Selected referral populations, inconsistent older definitions and nonrandom treatment decisions prevent a simple conversion of reported response rates into an individualized ranking.

Do not assume that treatment for DADA2, systemic PAN or an unrelated clotting disorder establishes treatment for ordinary skin-limited arteritis. A mechanism shared with another disorder can generate a research question without answering it clinically.

Document the purpose of each medicine: inflammation control, pain relief, infection treatment or another condition. Ask how benefit will be judged and how long the team will assess it before reconsidering. A clearer goal helps distinguish persistent damage from a plan that is failing to control new disease.

Risks, side effects and urgent warning signs

A rapidly worsening ulcer, blackened tissue, fever or spreading painful redness needs prompt assessment. New weakness, significant numbness or loss of limb function also needs attention. The NHLBI symptom information explains why a changing organ pattern should not be dismissed as a skin flare.

Stroke symptoms, severe unexplained chest/abdominal pain, collapse or a threatened cold/painful limb warrant emergency help. The original skin-limited diagnosis is relevant history, but it does not establish that every subsequent symptom has the same cause.

Glucocorticoids can cause infection, bone, metabolic and mood/sleep problems. NHS safety information. Disease control and treatment harm should be reviewed together. Symptoms during treatment can come from either, and professional assessment may be needed to distinguish them.

Colchicine has important toxicity risks, including with excessive dosing or interacting medicines. NHS medicine guidance. Its usual use for gout is not a reason to borrow a gout regimen for cutaneous PAN. A dosing error requires urgent professional advice.

Interactions and situations needing extra care

Colchicine can interact with several antibiotics, antiviral medicines, statins and heart medicines; grapefruit also matters. NHS interaction guidance. Tell the person prescribing a new infection treatment that colchicine is already being taken, rather than assuming short courses are automatically safe.

NSAIDs, aspirin and herbal products need review alongside prednisolone. NHS steroid interaction information. A pain-relief medicine can add gastrointestinal or other risk, especially when the diagnosis or another medicine already creates complications.

If methotrexate is used, check antibiotic and supplement compatibility, particularly trimethoprim/co-trimoxazole. NHS methotrexate interactions. Review the whole list with the pharmacist; medicines described as supportive or preventive can still interact.

Pregnancy planning, liver/kidney problems and infection history may change the choice of immune-directed treatment. The care team should give medicine-specific advice. Do not add aspirin or anticoagulation simply because skin lesions reflect impaired circulation; the cause and bleeding context need assessment.

Who needs assessment

Persistent painful nodules, livedo with ulcers or a suspected skin vasculitis need clinical evaluation rather than repeated empirical cosmetic treatment. Dermatology may coordinate with rheumatology and other specialists if symptoms suggest wider disease. Bring prior biopsy reports and medicines, including recent new prescriptions.

Childhood onset, early unexplained stroke, recurrent inflammatory episodes or a family pattern can prompt assessment for DADA2. The 2023 original consensus treats this as a separate inherited disorder with potentially vascular, immune and blood-cell problems. Not every person with cutaneous PAN has DADA2.

A change in blood pressure, urinary findings, abdominal symptoms or symptoms distant from the skin lesions should be reported. The team decides whether it changes the diagnosis or requires testing. “Skin-limited” describes the assessed disease distribution; it is not permission to ignore a new organ complaint.

Clinician-led treatment and practical use

Ask for a written plan that names the diagnosis, the evidence supporting skin limitation, the intended treatment outcome and the contact route for deterioration. Record ulcer size/site and functional limitations where the team considers this useful. Avoid changing several treatments at once without coordination.

If long-term prednisolone is prescribed, do not stop it suddenly or improvise a taper. NHS stopping guidance. A plan for reduction needs to account for both the inflammatory condition and the body’s response to prolonged steroid exposure.

Methotrexate for inflammatory disease is generally taken weekly; accidentally taking it daily requires urgent professional advice. NHS administration safety. Prescribed folate and blood monitoring serve medicine safety; they do not demonstrate that folate treats skin arteries.

Ask which follow-up findings indicate active inflammation, healing, infection or lasting nerve/skin damage. A wound-care or rehabilitation plan can remain important after inflammation improves. Continuing functional difficulty deserves review even if the blood markers are reassuring.

Animal and in vitro evidence

Experimental work explores immune complexes, vascular antibodies and inflammatory pathways. The original review discusses anti-LAMP-2 and related model findings. These are hypotheses and model observations, not validated consumer blood-test thresholds or proof of a supplement effect.

A treatment verdict needs meaningful human outcomes, adequate comparison and traceable funding. An antibody signal or less inflammation in an experimental vessel does not establish durable ulcer healing, relapse prevention or safe long-term treatment in people. Such findings are excluded from this guide’s efficacy verdict.

Funding and source roles

The Japanese original names a public ministry grant; its age, sample and incomplete author chain still limit conclusions. Other reviews have no-conflict/unsponsored declarations but incomplete wider financial chains. DermNet is society-owned and explicitly has advertising, sponsorship and affiliate income; its dated symptom education is used narrowly. Its older drug anecdotes, imprecise histology wording and DADA2-treatment discussion are not adopted as current evidence. The mixed-interest international DADA2 consensus is attributed. A later original CZI report documents DADA2 Foundation enzyme-compound/patent and diagnostic-development interests; these do not establish efficacy. No manufacturer-funded efficacy is used to rank treatments.

Tier describes financial proximity; A–D describes credibility for the stated source role. Neither is a clinical certainty grade. Unknown finances remain unknown. Manufacturer- and sponsor-funded efficacy is excluded from the independent verdict; attributed clinical guidance is identified as guidance.

Frequently asked questions

Is cutaneous PAN the same as systemic PAN?
No. It is a distinct skin-limited arterial vasculitis, though skin findings can look similar. Assessment determines whether other organs are involved.

Can it cause nerve symptoms?
Local symptoms near affected skin can occur. New or wider neurologic findings require reassessment rather than an assumption that they are harmless.

Can a superficial biopsy exclude it?
Not reliably. The relevant arteries can lie deep in the skin/subcutaneous tissue; the clinical/pathology team chooses the sample.

Is one medicine proven best?
No definitive independent ranking is established here. Severity, ulcers, nerve findings, recurrence, safety and uncertain evidence guide specialist decisions.

Should everyone be tested for DADA2?
Testing depends on the clinical pattern, age, family history and associated findings. Genetic disease is a distinct possibility, not an automatic explanation of every skin case.

Sources and funding notes

Full originals were checked for the 2012 Japanese review, 2022 cutaneous-arteritis review, August 2026 PAN-related review and 2023 DADA2 consensus. Public medication pages were read for safety only; older prednisolone/methotrexate page dates are retained in their source profiles. Colchicine’s current consolidated page was reviewed August 20, 2026. DermNet’s clinical page was last updated January 2016; older anecdotes are excluded. No cohort response percentages, personal doses, universal compression instruction or claim that progression can never occur is supplied. The systemic ACR guideline expressly excludes cutaneous PAN.

• Furukawa: original 2012 cutaneous PAN review/retrospective findings — Deep arterial biopsy, scope and dated treatment limitations; no remission percentage or guarantee of no systemic disease.
• Ikeda: original 2022 cutaneous arteritis review — Cutaneous arteritis synonyms, local neuropathy, differential diagnosis and model limitations.
• Watts: original August 2026 PAN-related review — Skin-limited versus systemic/etiologic classification; no sponsor-cleared drug ranking.
• DermNet: cutaneous PAN page, January 2016 — Symptom/ulcer context only; older DADA2-treatment and warfarin anecdotes not adopted.
• DermNet: ownership and editorial description — Publisher identity only.
• DermNet: donation/revenue disclosure — Revenue and attribution limits only.
• DermNet: advertising policy — Declared editorial separation, not proof of independence.
• Lee/Ombrello et al.: original 2023 international DADA2 consensus — Phenotype-specific assessment, treatment and antithrombotic caution; no unqualified drug-effect estimate.
• CZI: original December 2024 Rare-As-One impact report, DADA2 pages — Funding and patent/diagnostic interests only.
• ACR/VF: original 2021 PAN management guideline — Dated clinical framework; no cleared drug-effect percentages.
• ACR: corporate support opportunities — Revenue model only.
• Vasculitis Foundation: audited FY 2024–25 accounts — Institutional funding model only.
• Vasculitis Foundation: awareness fundraising sponsors — Named commercial relationship only.
• NHLBI: vasculitis overview (May 2023) — Disease-family definition and vessel-size context; not cleared treatment trials.
• NHLBI: causes (May 2023) — Possible triggers and secondary causes; not an individual causal diagnosis.
• NHLBI: symptoms (May 2023) — Organ-specific manifestations and complications.
• NHLBI: diagnosis (May 2023) — Clinical, blood, urine, biopsy and imaging assessment; subtype-specific accuracy not assumed.
• NHLBI: treatment (May 2023) — Attributed general treatment context, not a comparative efficacy verdict.
• NHLBI: living with vasculitis (May 2023) — Follow-up, pregnancy planning and emergency complications; individual risks differ.
• NHLBI: budget and gift authority — Funding trace, not outcome evidence.
• NHS: prednisolone side effects — Infection, bone, metabolic and mood risks; medicine safety, not disease-specific efficacy.
• NHS: prednisolone use and stopping (February 2022) — Clinician-directed tapering and adrenal safety; stated review date has passed.
• NHS: prednisolone interactions (February 2022) — NSAID/aspirin and supplement cautions; dated general medicine context.
• NHS: methotrexate use (March 2023) — Weekly inflammatory-disease administration safety and monitoring; no personal dose.
• NHS: methotrexate interactions (March 2023) — Antibiotic, NSAID, supplement and vaccine review; stated review date has passed.
• NHS website: content and funding policy — Website funding and editorial safeguards only.
• NCCIH: using dietary supplements wisely — Safety and interaction limits, not proof of vasculitis efficacy.
• NHS: colchicine medicine safety — General toxicity/administration safety; licensing for gout does not establish cutaneous-PAN efficacy.
• NHS: colchicine interactions — Antibiotic, antiviral, statin/heart-medicine and grapefruit cautions; general medication safety.

Last reviewed: October 4, 2026. Educational information; no personal diagnosis, medication dose or supplement regimen is supplied. Local approval, product labels and clinical circumstances may differ.